Regulatory approval of the first two therapeutic substances for the management of
geographic atrophy (GA) secondary to age-related macular degeneration (AMD) is a major …

Current Opinion in Ophthalmology Log in or Register Subscribe to journalSubscribe Get new
issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …

Purpose To determine whether oral micronutrient supplementation slows geographic
atrophy (GA) progression in age-related macular degeneration (AMD). Design Post hoc …

Purpose: To examine deep learning (DL)–based methods for accurate segmentation of
geographic atrophy (GA) lesions using fundus autofluorescence (FAF) and near-infrared …

Background Imaging plays a pivotal role in eye assessment. With the introduction of
advanced machine learning and artificial intelligence (AI), the focus has shifted to imaging …

Featured Application This study shows promising results for the development of artificial
intelligence tools for the predicting of the progression of Stargardt disease. It further offers …

Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration
(AMD) that leads to progressive and irreversible vision loss. Identifying patients with greatest …

The human population is steadily growing with increased life expectancy, impacting the
prevalence of age-dependent diseases, including age-related macular degeneration (AMD) …

The power of randomized controlled clinical trials to demonstrate the efficacy of a drug
compared with a control group depends not just on how efficacious the drug is, but also on …

Identification of GA and of risk factors for GA development or progression is essential when
counseling AMD patients and discussing prognosis. With new therapies on the horizon for …